GlassScriptPhysician profile
Melanie Redfield
NPI 1811278450
$1,124.39
in general payments reported to CMS, 2019-2025
22 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $228 · 2022: $223 · 2023: $108 · 2024: $412 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $239.74 | 2021-2024 | |
| Organon LLC | $128.46 | 2021-2025 | Nexplanon |
| Boston Scientific Corporation | $103.14 | 2024 | Versacross Access Solution |
| Mayne Pharma Commercial LLC | $70.23 | 2021-2025 | |
| Hologic Sales and Service, LLC | $66.30 | 2022-2025 | Thinprep 2000 Processor, Aptima, Novasure |
| Sumitomo Pharma America, INC. | $63.12 | 2023-2024 | Myfembree |
| Merck Sharp & Dohme LLC | $59.48 | 2021-2024 | Gardasil, Gardasil 9 |
| Astellas Pharma US INC | $55.62 | 2024 | Veozah |
| Sage Therapeutics, LLC | $48.48 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $44.49 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $38.60 | 2023-2024 | Bd Onclarity |
| Exeltis, USA INC. | $30.39 | 2024 | Slynd |
| Exact Sciences Corporation | $26.78 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $20.01 | 2022 | |
| Daiichi Sankyo INC. | $18.63 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $18.19 | 2024 | Bd Onclarity |
| Ascend Therapeutics US, LLC | $17.83 | 2021 | |
| Avion Pharmaceuticals | $16.20 | 2021 | |
| Coopersurgical, INC. | $15.89 | 2024 | Paragard T 380a |
| Shield Therapeutics INC | $14.91 | 2023 | |
| Pfizer INC. | $14.64 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.26 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Redfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.